These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 16289236

  • 1. Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
    Hagiwara H, Sato H, Shirai S, Kobayashi S, Fukumoto K, Ishida T, Seki T, Ariga T, Yano T.
    Life Sci; 2006 Apr 04; 78(19):2249-54. PubMed ID: 16289236
    [Abstract] [Full Text] [Related]

  • 2. The inhibitory effect of connexin 32 gene on metastasis in renal cell carcinoma.
    Sato H, Hagiwara H, Senba H, Fukumoto K, Nagashima Y, Yamasaki H, Ueno K, Yano T.
    Mol Carcinog; 2008 Jun 04; 47(6):403-9. PubMed ID: 18058801
    [Abstract] [Full Text] [Related]

  • 3. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V, Schroeder J, Kristiansen G, Roigas J, Denkert C, Johannsen M, Lein M, Loening SA, Schnorr D, Jung K, Staack A.
    Oncol Rep; 2005 Sep 04; 14(3):777-82. PubMed ID: 16077991
    [Abstract] [Full Text] [Related]

  • 4. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 04; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of Src activity enhances the tumor-suppressive effect of the connexin 32 gene in Caki-1 renal cancer cells.
    Fujimoto E, Sato H, Shirai S, Nagashima Y, Virgona N, Hagiwara K, Yamasaki H, Negishi E, Ueno K, Yano T.
    Oncol Rep; 2006 May 04; 15(5):1359-65. PubMed ID: 16596211
    [Abstract] [Full Text] [Related]

  • 6. A Src family inhibitor (PP1) potentiates tumor-suppressive effect of connexin 32 gene in renal cancer cells.
    Fujimoto E, Sato H, Nagashima Y, Negishi E, Shirai S, Fukumoto K, Hagiwara H, Hagiwara K, Ueno K, Yano T.
    Life Sci; 2005 Apr 22; 76(23):2711-20. PubMed ID: 15792837
    [Abstract] [Full Text] [Related]

  • 7. Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line.
    Fujimoto E, Sato H, Shirai S, Nagashima Y, Fukumoto K, Hagiwara H, Negishi E, Ueno K, Omori Y, Yamasaki H, Hagiwara K, Yano T.
    Oncogene; 2005 May 19; 24(22):3684-90. PubMed ID: 15782139
    [Abstract] [Full Text] [Related]

  • 8. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD, Tomaso H, Mengele K, Schilling D, Bayer C, Stadler P, Schmitt M, Molls M.
    Oncol Rep; 2007 May 19; 17(5):1259-68. PubMed ID: 17390074
    [Abstract] [Full Text] [Related]

  • 9. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
    Sato H, Senba H, Virgona N, Fukumoto K, Ishida T, Hagiwara H, Negishi E, Ueno K, Yamasaki H, Yano T.
    Mol Carcinog; 2007 Mar 19; 46(3):215-24. PubMed ID: 17186540
    [Abstract] [Full Text] [Related]

  • 10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 19; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 11. Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
    Bobarykina AY, Minchenko DO, Opentanova IL, Moenner M, Caro J, Esumi H, Minchenko OH.
    Acta Biochim Pol; 2006 Jan 19; 53(4):789-99. PubMed ID: 17143338
    [Abstract] [Full Text] [Related]

  • 12. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K.
    J Lab Clin Med; 2004 Aug 19; 144(2):69-77. PubMed ID: 15322501
    [Abstract] [Full Text] [Related]

  • 13. The adaptor protein Ruk/CIN85 activates plasminogen activator inhibitor-1 (PAI-1) expression via hypoxia-inducible factor-1alpha.
    Samoylenko A, Dimova EY, Kozlova N, Drobot L, Kietzmann T.
    Thromb Haemost; 2010 May 19; 103(5):901-9. PubMed ID: 20216986
    [Abstract] [Full Text] [Related]

  • 14. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.
    Wakita T, Hayashi T, Nishioka J, Tamaru H, Akita N, Asanuma K, Kamada H, Gabazza EC, Ido M, Kawamura J, Suzuki K.
    Int J Cancer; 2004 Feb 10; 108(4):516-23. PubMed ID: 14696115
    [Abstract] [Full Text] [Related]

  • 15. Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck.
    Artman T, Schilling D, Gnann J, Molls M, Multhoff G, Bayer C.
    Int J Radiat Oncol Biol Phys; 2010 Feb 01; 76(2):574-82. PubMed ID: 20117293
    [Abstract] [Full Text] [Related]

  • 16. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
    Buø L, Bjørnland K, Karlsrud TS, Kvale D, Kjønniksen I, Fodstad O, Brandtzaeg P, Johansen HT, Aasen AO.
    Anticancer Res; 1994 Feb 01; 14(6B):2445-51. PubMed ID: 7872665
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T.
    BMC Cell Biol; 2006 Feb 20; 7():8. PubMed ID: 16504015
    [Abstract] [Full Text] [Related]

  • 18. Negative growth control of renal cell carcinoma cell by connexin 32: possible involvement of Her-2.
    Fujimoto E, Satoh H, Negishi E, Ueno K, Nagashima Y, Hagiwara K, Yamasaki H, Yano T.
    Mol Carcinog; 2004 Jul 20; 40(3):135-42. PubMed ID: 15224345
    [Abstract] [Full Text] [Related]

  • 19. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A, Xue M, Jackson C, Smith RC.
    Int J Biochem Cell Biol; 2009 Jul 20; 41(8-9):1731-8. PubMed ID: 19433314
    [Abstract] [Full Text] [Related]

  • 20. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U, Prenzel KL, Baldus SE, Metzger R, Dienes HP, Bollschweiler E, Hoelscher AH, Schneider PM.
    Pancreas; 2008 Mar 20; 36(2):173-7. PubMed ID: 18376309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.